Emerging

NCPDP Announces its 2024 Champion Award Recipient at #NCPDP24

Retrieved on: 
星期三, 五月 8, 2024
Work Group, Task force, Pharmacy, Pharmacist, NCPDP, Policy, Conference, ONC, Patient safety, Government, Physician, HIT, Health, HITAC, Emerging, Meeting, Therapy, Pharmaceutical industry

SCOTTSDALE, Ariz., May 8, 2024 /PRNewswire-PRWeb/ -- Today at its Annual Technology & Business Conference, NCPDP announced its 2024 Champion Award recipient, Shelly Spiro, Executive Director at Pharmacy HIT Collaborative and President and CEO of Spiro Consulting. NCPDP's Champion Award recognizes outstanding accomplishments or work to improve patient care by actively supporting NCPDP members and its initiatives.

Key Points: 
  • SCOTTSDALE, Ariz., May 8, 2024 /PRNewswire-PRWeb/ -- Today at its Annual Technology & Business Conference, NCPDP announced its 2024 Champion Award recipient, Shelly Spiro, Executive Director at Pharmacy HIT Collaborative and President and CEO of Spiro Consulting.
  • NCPDP's Champion Award recognizes outstanding accomplishments or work to improve patient care by actively supporting NCPDP members and its initiatives.
  • NCPDP President & CEO Lee Ann Stember stated, "We are pleased to present this award to Shelly, a long-time participant of NCPDP, Work Group Co-Chair and Leader of multiple Task Groups.
  • For real-time updates during the conference, follow @NCPDP on X, NCPDP on LinkedIn, or join the discussion using the hashtag: #NCPDP24.

Sara Rouhi joins AIP Publishing as Director of Open Science and Publishing Innovation

Retrieved on: 
星期二, 四月 30, 2024
Society, American Institute of Physics, CPO, PLOS, Communication, Partnership, SSP, Research, Public, AIP, Multimedia, Emerging, Management

"AIPP has a storied history as researcher-focused non-profit committed to putting science first," Rouhi said. "I'm honored to join a leadership team not only committed to forging an equitable open science path but also deeply invested in building a workplace culture grounded in humility, experimentation, and embracing change. AIPP -- thanks to its cultural transformation and its open science investment -- stands poised to contribute meaningfully and substantively to the furthering of open science globally."

Key Points: 
  • MELVILLE, N.Y., April 30, 2024 /PRNewswire/ -- AIP Publishing (AIPP) announced today that Sara Rouhi has joined the organization in the new role of Director of Open Science and Publishing Innovation.
  • AIPP -- thanks to its cultural transformation and its open science investment -- stands poised to contribute meaningfully and substantively to the furthering of open science globally."
  • Rouhi joins AIP Publishing from Public Library of Science (PLOS) where she was Regional Director, Publishing Development, The Americas.
  • I'm thrilled that Sara will join us in driving open science innovation that truly benefits the physical sciences community."

QIAGEN expands tuberculosis portfolio with new NGS Panel to support real-time surveillance and combat antimicrobial resistance

Retrieved on: 
星期三, 四月 24, 2024
TST, Genetically modified bacteria, WHO, Virtual reality, CDC, Multidrug-resistant tuberculosis, Bacteria, AMR, ESCMID, QIAGEN, ECCMID, MDR-TB, WGS, Doctor of Philosophy, Research, Workflow, Sputum, NGS, PCR, Disease, Patient, Panel, Mycobacterium tuberculosis, QGEN, Gold, Infection, D20, Emerging, Tuberculosis, Cerebrospinal fluid, Vaccine

The QIAseq xHYB Mycobacterium tuberculosis Panel represents a major advancement in solving the problem of bacterial WGS from complex host samples, using next-generation sequencing (NGS).

Key Points: 
  • The QIAseq xHYB Mycobacterium tuberculosis Panel represents a major advancement in solving the problem of bacterial WGS from complex host samples, using next-generation sequencing (NGS).
  • By eliminating the need for a 4-to-6-week bacterial culture, the panel significantly accelerates the process of obtaining results.
  • “The introduction of the QIAseq xHYB Mycobacterium tuberculosis Panel reflects our ongoing commitment to address global health challenges like TB and antimicrobial resistance,” said Nitin Sood, Vice President, Head of the Life Sciences Business Area at QIAGEN.
  • The QIAseq xHYB Mycobacterium tuberculosis Panel also plays a vital role in the detection and management of antimicrobial resistance (AMR), a growing concern in TB treatment.

CND Life Sciences to Highlight Momentum of Skin Biopsy Diagnostic Tool for Parkinson’s Disease and Related Disorders at the American Academy of Neurology 2024 Annual Meeting

Retrieved on: 
星期五, 四月 12, 2024
Medical Devices, Other Health, Health, Science, Research, Neurodegenerative disease, PAF, American Academy, Lewy body, MCI, CND, DLB, NIH, Skin, Autonomic nervous system, Abstract, MD, Artificial intelligence, Colorado Convention Center, Dementia, Tremor, Patient, AAN, Orthostatic hypotension, Neurology, Harvard Medical School, Diagnosis, Emerging, Biomarker, Algorithm

The results are focused on patients with dementia with Lewy bodies (DLB) and mild cognitive impairment (MCI).

Key Points: 
  • The results are focused on patients with dementia with Lewy bodies (DLB) and mild cognitive impairment (MCI).
  • A second abstract being presented describes the utility of the synuclein skin biopsy in the initial diagnosis and evaluation of Parkinsonian disorders in everyday clinical practice.
  • “All of the research that will be presented during AAN supports the groundbreaking diagnostic advances using skin biopsies to detect, quantify, and monitor neurodegenerative disease progression.
  • Details on relevant presentations are as follows:
    Essential Tremor with Parkinsonism with Normal Dopamine Transporter Imaging: Majority Have Evidence of Peripheral Synucleinopathy

Canaan Adds Accomplished Executive and Scientist, Uwe Schoenbeck, Ph.D., Along with New Capital, to Bolster its Biopharma Investment Efforts

Retrieved on: 
星期三, 四月 17, 2024
Investment, Cell biology, Boehringer Ingelheim, News, Hospital, Abstract, Cardiology, CTI, WRDM, Partnership, Research, Brigham, Development, Cardiovascular Research, Therapy, Brigham and Women's Hospital, Senior, Science, Translation, Inflammatory bowel disease, Patient, Neurology, Acquisition, Initial public offering, General partnership, Metabolism, Harvard Medical School, Health, Assistant, Emerging, Biotechnology, Pharmaceutical industry

MENLO PARK, Calif., April 17, 2024 /PRNewswire/ -- Canaan, a venture capital firm that invests in entrepreneurs with visionary ideas, announced the addition of Uwe Schoenbeck, Ph.D., to its healthcare investment team as a new Venture Partner. Dr. Schoenbeck's impressive career has spanned more than 25 years in the life science and healthcare industry, as well as academia, providing him with an exceptional global network among leading research institutions, biotechnology and biopharmaceutical companies, and venture firms. He is highly regarded for his contributions in enabling and translating emerging science into breakthrough therapies, reaching from scientific collaborations, licensing, and acquisition deals to venture investing. In joining Canaan's healthcare investment team, Dr. Schoenbeck will help drive new investments and company creation from Canaan XIII, the firm's latest fund, by bringing in deep scientific and pharmaceutical perspectives, while also serving as a valuable resource to companies across the firm's existing biopharma portfolio. To this end, he has already facilitated his first investment as a member of the team, leading Canaan's participation in the recently announced $132 million Series B financing for Alterome Therapeutics and being named a member of the company's board of directors.

Key Points: 
  • Most recently, Dr. Schoenbeck served as Senior Vice President and Chief Scientific Officer Emerging Science & Innovation (ES&I) in Pfizer's Worldwide Research, Development & Medical (WRDM) division.
  • In leading ES&I, he worked to harness external breakthrough science, assets, and technologies by leveraging a broad range of partnering vehicles.
  • "It is not often that we have the opportunity to add someone of Uwe's caliber and track record to the Canaan investment team.
  • In additional news, Canaan today reported that it has expanded the size of its biopharma investment funds with the addition of more than $100 million in new capital.

Government of Canada hosts 10th Canada's Volunteer Awards ceremony and launches call for nominations

Retrieved on: 
星期一, 四月 15, 2024
Education, United Nations, Volunteering, Boys & Girls Club, Social change, Organization, National Volunteer Week, Hub, Statistics, International Dyslexia Association, Call, Ageing, QC, Cove, Nomination, Sustainability, Award, Food security, Survivor, GlobalMedic, Sandbox, Columbia, Emerging, National Arts Centre, Robin, Hamilton Health Sciences, Prairie, Statistics Canada, Simulation, Parlement, Nursing

Canada's Volunteer Awards highlight community leadership and aim to encourage people from across Canada to make a difference in their communities through volunteering, while developing innovative solutions to tackle social challenges.

Key Points: 
  • Canada's Volunteer Awards highlight community leadership and aim to encourage people from across Canada to make a difference in their communities through volunteering, while developing innovative solutions to tackle social challenges.
  • Starting today, nominations are being accepted for an individual or group of volunteers, a not-for-profit organization, a social enterprise or a business.
  • "I extend a heartfelt invitation for you to nominate outstanding individuals for the Emerging Leader Award through Canada's Volunteer Awards.
  • Canada's Volunteer Awards consist of 21 awards: 20 awards at the regional level and one award at the national level.

Hispanic-Serving Institutions Across The Nation Total 600

Retrieved on: 
星期三, 三月 20, 2024
University, Growth, Integration, SAN, IPEDS, Emerging, Student, FTE, Social, HACU, Pell, SMI, HSI

In 2022-23, there were 600 institutions that met the definition of an HSI compared to 572 in 2021-22.

Key Points: 
  • In 2022-23, there were 600 institutions that met the definition of an HSI compared to 572 in 2021-22.
  • This increase of 28 institutions or 5% from the previous year, highlights the continued growth in Hispanic student enrollment at colleges and universities across the country.
  • “The rate that Hispanic-Serving Institutions continue to grow emphasizes their importance to the communities they serve,” said HACU President and CEO Antonio R. Flores.
  • In 2022-23, HSIs enrolled 66.2% of all Hispanic undergraduates and 31.7% of all undergraduate students in nonprofit postsecondary education.

SENISCA secures additional £3.7 million financing to support rapid development of senotherapeutic platform to treat age-related disease

Retrieved on: 
星期一, 三月 18, 2024
Stem cell, Patient, Ageing, RNA, Longevity, University, Emerging, RNA splicing, Innovate UK, Notifiable disease, Innovation, Vaccine

£3.7 million seed financing supported by consortium of new and existing investors will fund continued preclinical development of therapeutic pipeline programmes.

Key Points: 
  • £3.7 million seed financing supported by consortium of new and existing investors will fund continued preclinical development of therapeutic pipeline programmes.
  • Exeter, UK — 18 March 2024: SENISCA, an award-winning biotechnology company developing RNA-based senotherapeutics to treat age-related disease, today announces it has raised an additional £3.7 million in funding.
  • Dr Sarah Cole, CEO of SENISCA, commented: “This financing round represents another significant milestone for SENISCA.
  • SENISCA has undergone a significant and rapid development and QantX is looking forward to working with the team to realise the full potential of the Company’s disruptive senotherapeutic technology.”

Datopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancer

Retrieved on: 
星期二, 四月 2, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, MSD, Breast cancer, Goserelin, Patient, Lung, Social media, Immunoglobulin G, National Cancer Institute, Neoplasm, Merck & Co., TNBC, Capecitabine, DXD, BRCA, Clinical Cancer Research, Metabolism, Immunology, Biopharmaceutical, World Health Organization, Cancer, Safety, ADC, BLA, Daiichi Sankyo, Vinorelbine, IHC, Mutation, NSCLC, Disease, Merck, AKT, Death, MD, AstraZeneca, PARP, Oncotarget, PFS, FDA, OS, HER2, Eribulin, Cleavage, Progression-free survival, Triple-negative breast cancer, Female, Emerging, Olaparib, Biology, Sapporo Medical University, Medicine, Pharmaceutical industry

The safety profile of datopotamab deruxtecan was consistent with that observed in other ongoing trials with no new safety concerns identified.

Key Points: 
  • The safety profile of datopotamab deruxtecan was consistent with that observed in other ongoing trials with no new safety concerns identified.
  • Additional regulatory submissions for datopotamab deruxtecan in lung and breast cancer are underway globally.
  • A comprehensive global clinical development program is underway with more than 20 trials evaluating the efficacy and safety of datopotamab deruxtecan across multiple cancers, including NSCLC, triple-negative breast cancer (TNBC) and HR-positive, HER2-negative breast cancer.
  • Comparative Overall Survival of CDK4/6 Inhibitors Plus Endocrine Therapy vs. Endocrine Therapy Alone for Hormone receptor-positive, HER2-negative metastatic breast cancer.

DUNN-EDWARDS HOSTS ANNUAL STUDENT DESIGN COMPETITION

Retrieved on: 
星期二, 四月 2, 2024
Travel, Social media, Blog, UCLA Extension, Postgraduate education, Skipping Stones, Emerging, Student, Harvard University, Creativity, LOS, Nippon Paint, Marketing, UCLA, Interior architecture, Interior design

LOS ANGELES, April 2, 2024 /PRNewswire/ -- Dunn-Edwards fourth annual Emerging Professionals Design Competition was officially opened for submissions today nationwide. Current architecture and design students who are enrolled in school can submit their entry online now through August 18, 2024. There is no fee to enter. Winners will be announced by September 30, 2024.

Key Points: 
  • LOS ANGELES, April 2, 2024 /PRNewswire/ -- Dunn-Edwards fourth annual Emerging Professionals Design Competition was officially opened for submissions today nationwide.
  • Winners of the AYDA Awards will attend the three-week, all-expenses-paid Design Discovery Programme at Harvard University's Graduate School of Design.
  • Each entrant will be required to include the color, born from Dunn-Edwards 2024 Color + Design Trends, in their design.
  • For more details about Dunn-Edwards 2024 Emerging Professionals Design Competition, visit www.dunnedwards.com .